首页> 外文期刊>Blood cells, molecules and diseases >BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients
【24h】

BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients

机译:T细胞急性淋巴细胞白血病患者的BCL11B,FLT3,NOTCH1和FBXW7突变状态

获取原文
获取原文并翻译 | 示例
       

摘要

T-cell acute lymphoblastic leukemia is a heterogeneous malignancy originating from developing lymphocyte precursors likely due to mutations in genes regulating thymocyte differentiation. Here, we characterized mutation status of BCL11B and FLT3 genes, presumably involved in T-ALL, together with FBXW7 and NOTCH1 as known players in T-ALL in 65 pediatric T-cell acute lymphoblastic leukemia patients. We also aimed at the assessment of prognostic value of NOTCH1 and FBXW7 mutations in ALL-IC BFM 2002 protocol.FLT3 and BCL11B mutations were detected in 3% and 2% of patients, respectively. FBXW7 mutations were observed in 8% of patients, while NOTCH1 was mutated in 40%. No correlation was found between NOTCH1 and FBXW7 mutations and traditionally used clinical factors or molecular features. In total we have detected nine mutations, which have not been previously described by others. Eight of them were found in NOTCH1 and one in BCL11B gene.Observed frequencies of NOTCH1 and FBXW7 are in line with previous reports, thus confirming postulated participation of these two genes in T-ALL pathomechanism. Moreover, we report on mutation frequency of FLT3 and BCL11B, not extensively studied in T-ALL so far. Finally, we suggest a putative role of BLC11B as an oncogene in T-ALL pathogenesis.
机译:T细胞急性淋巴细胞白血病是一种异质性恶性肿瘤,起源于发展中的淋巴细胞前体,可能是由于调节胸腺细胞分化的基因突变所致。在这里,我们表征了65例小儿T细胞急性淋巴细胞白血病患者中BCL11B和FLT3基因(可能与T-ALL一起)以及FBXW7和NOTCH1的突变状态,作为T-ALL中的已知参与者。我们还旨在评估ALL-IC BFM 2002方案中NOTCH1和FBXW7突变的预后价值。分别在3%和2%的患者中检测到FLT3和BCL11B突变。在8%的患者中观察到FBXW7突变,而在40%的患者中观察到NOTCH1突变。在NOTCH1和FBXW7突变与传统使用的临床因素或分子特征之间未发现相关性。总的来说,我们已经检测到9个突变,其他人以前没有描述过。在NOTCH1中发现了8个,在BCL11B基因中发现了1个.NOTCH1和FBXW7的观察频率与以前的报道相符,从而证实了这两个基因的推测参与T-ALL发病机制。此外,我们报道了迄今为止尚未在T-ALL中广泛研究的FLT3和BCL11B的突变频率。最后,我们建议BLC11B作为癌基因在T-ALL发病机理中的假定作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号